Table 1.
Mouse strain/treatment | Tumor | Site of metastasis tested | Number of tumor metastases | ||
---|---|---|---|---|---|
Control | IL-12 treated | % inhibition | |||
BALB/c + IL-12 | RL♂1 | liver | 216 ± 24 | 28 ± 2 | 87%* |
Colon 26 | lung | 125 ± 25 | 16 ± 10 | 87%* | |
DBA/2 + lL-12 | P815 | liver | 173 ± 12 | 10 ± 1 | 94%* |
C57BL/6 + IL-12 | B16 | lung | 61 ± 16 | 5 ± 1 | 91%* |
EL4 | liver | 106 ± 22 | 17 ± 7 | 84%* | |
C57BL/6 bg/bg + IL-12 | EL4 | liver | 107 ± 17 | 16 ± 6 | 85%* |
| |||||
C57BL/6 + IL-12 | EL4 | liver | 96 ± 18 | 15 ± 4 | 84%* |
3LL | lung | 122 ± 26 | 25 ± 5 | 80%* | |
C57BL/6 + αAGM1 Ab + IL-12 | EL4 | liver | 102 ± 24 | 22 ± 5 | 78%* |
3LL | lung | 128 ± 32 | 33 ± 8 | 74%* | |
C57BL/6 + αNK1.1 Ab + IL-12 | EL4 | liver | 152 ± 26 | 130 ± 20 | 14% |
3LL | lung | 204 ± 36 | 156 ± 28 | 24% |
The mice were inoculated i.v. with syngeneic tumors. Data of tumor metastasis and % of inhibition are shown as mean ± SD from six to ten mice in each group. *P < .01. αAGM1 Ab: antiasialo GM1 antibody; αNK1.1 Ab: anti-NK1.1 antibody.